Trial reportJournal of the American Society of Nephrology : JASN2015
Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity.
Trial report in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05105009 (Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function), which is not on this map. Cited by 113 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Furosemide and Creatinine Tubular Stress Test in Order to Measure Proximal Tubule Residual Function: is It Better Than GFR?
Who cites it
113 citing papers in PubMed, 8 syntheses or guidelines pooled it.
- Predictive value of FST for renal replacement therapy in patients with acute kidney injury: a meta-analysis.Scientific reports · 2026Pooled it
- [S3 guideline on renal replacement therapy in intensive care medicine : Evidence-based implementation of renal replacement therapy in critically ill patients].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Guideline
- Systematic Review on the Management of Diuretic Resistance in Acute Heart Failure across the Spectrum of Kidney Disease.Cardiorenal medicine · 2025Pooled it
- Controversies in acute kidney injury: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference.Kidney international · 2020 · on this mapGuideline
- Furosemide stress test as a predictive marker of acute kidney injury progression or renal replacement therapy: a systemic review and meta-analysis.Critical care (London, England) · 2020Pooled it
- Biomarkers for prediction of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis.Intensive care medicine · 2018Pooled it
- Intermittent furosemide administration in patients with or at risk for acute kidney injury: Meta-analysis of randomized trials.PloS one · 2018Pooled it
- Systematic review of prognostic prediction models for acute kidney injury (AKI) in general hospital populations.BMJ open · 2017Pooled it
- Differential effect on mortality of the timing of initiation of renal replacement therapy according to the criteria used to diagnose acute kidney injury: an IDEAL-ICU substudy.Critical care (London, England) · 2023Trial
- The furosemide stress test predicts the timing of continuous renal replacement therapy initiation in critically ill patients with acute kidney injury: a double-blind prospective intervention cohort study.European journal of medical research · 2023Trial
- Early versus standard initiation of renal replacement therapy in furosemide stress test non-responsive acute kidney injury patients (the FST trial).Critical care (London, England) · 2018Trial
- Predicting acute kidney injury at hospital re-entry using high-dimensional electronic health record data.PloS one · 2018Trial
- Personalized Sequential Nephron Blockade for Diuretic Resistance in Acute Decompensated Heart Failure: A Narrative Review for the Cardiorenal Clinician.Journal of personalized medicine · 2026Review
- Refining AKI Diagnosis: Is There a Return on the Investment?Kidney international reports · 2026Article
- Early Prediction of Acute Kidney Injury Using the Furosemide Stress Test in Pediatric Cardiac Surgery Patients.Children (Basel, Switzerland) · 2026Article
- Pre-CRRT furosemide and mortality in sepsis-associated AKI: A retrospective cohort study.PloS one · 2026Article
- Association Between the Modified Furosemide Response Index and Prognosis in Patients with Chronic Kidney Disease: A Retrospective Cohort Study Based on the MIMIC-IV Database.International journal of nephrology and renovascular disease · 2026Article
- Urine Olfactomedin 4 Predicts Furosemide Response and Kidney Replacement Therapy in Critically Ill Children.Critical care explorations · 2025Observational
- Furosemide Stress Test Use in Children at Risk for Acute Kidney Injury.Kidney international reports · 2025Article
- From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury.Hepatology (Baltimore, Md.) · 2025Review
53 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
Clinicians have access to limited tools that predict which patients with early AKI will progress to more severe stages. In early AKI, urine output after a furosemide stress test (FST), which involves intravenous administration of furosemide (1.0 or 1.5 mg/kg), can predict the development of stage 3 AKI. We measured several AKI biomarkers in our previously published cohort of 77 patients with early AKI who received an FST and evaluated the ability of FST urine output and biomarkers to predict the development of stage 3 AKI (n=25 [32.5%]), receipt of RRT (n=11 [14.2%]), or inpatient mortality (n=16 [20.7%]). With an area under the curve (AUC)±SEM of 0.87±0.09 (P<0.0001), 2-hour urine output after FST was significantly better than each urinary biomarker tested in predicting progression to stage 3 (P<0.05). FST urine output was the only biomarker to significantly predict RRT (0.86±0.08; P=0.001). Regardless of the end point, combining FST urine output with individual biomarkers using logistic regression did not significantly improve risk stratification (ΔAUC, P>0.10 for all). When FST urine output was assessed in patients with increased biomarker levels, the AUC for progression to stage 3 improved to 0.90±0.06 and the AUC for receipt of RRT improved to 0.91±0.08. Overall, in the setting of early AKI, FST urine output outperformed biochemical biomarkers for prediction of progressive AKI, need for RRT, and inpatient mortality. Using a FST in patients with increased biomarker levels improves risk stratification, although further research is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.